Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

home > ebr

PUBLICATIONS

European BioPharmaceutical Review

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:
Advertising Neil Clarke Yvette Allen	Editorial Danielle Levett

View the digital version of EBR

	Subscribe
	Current Issue
	Archives
	Media Info
	Our Clients

Featured in this issue

BioRegional

Bob Smailes at LeidenUniversity outlines the research taking place at LeidenBioSciencePark, the leading life science park in the Netherlands.

Business Development and Financing

There is currently global political and economic pressure to reduce the costs of healthcare. Michael F Swanick at PricewaterhouseCoopers examines the impact that rising tax rates will have on the biopharmaceutical industry over the next year.

BioDevelopment and Regulatory

Quality assurance should be integral to clinical development and trials to ensure the accuracy of test results. Martin Crockard at Randox describes different types of analyses and explains that the choice of scheme should be dependent on the size, duration and complexity of the trial.

Edited by
Dr Helen Tayton-Martin,
Chief Operating Officer,
Adaptimmune Ltd

Published quarterly in
January, April,
July and October

EBR e-Book

Industry Events

PAT and Quality by Design for Biopharmaceuticals

25-26 May 2010, London, UK

Pharma IQ is delighted to announce the inaugural PAT and quality by design for biopharmaceuticals, being held in London on the 25th-26th May 2010. With PAT and quality by design techniques now established within the small molecules field the focus is shifting to application within the biopharmaceuticals arena, with key regulatory bodies such as the FDA and EMEA actively getting involved I pilot case studies. This event will bring together professionals specifically tasked with implementing PAT and QbD tools and techniques specifically within the bioprocess and bioproduction area.
More info >>

All events >>

News and Press Releases

Successful PA Consulting and ERBI Cambridge seminar for emerging companies points the way to economic recovery

A seminar and dinner held on 26 January at Clare College Cambridge for emerging companies and their investors focusing on Adapting to life in the new economic environment – the challenge for start-ups attracted full attendance, demonstrating that venture-backed companies may be ahead in planning for the future and leading the UK out of recession.
More info >>

All releases >>

Air Transport Publications